Vanda Pharmaceuticals (VNDA) Research & Development (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Research & Development of $28.4 million for Q1 2026, up 143.17% sequentially from -$65.9 million in Q4 2025, and down 20.38% YoY from $35.7 million in Q1 2025.
Vanda Pharmaceuticals (VNDA) Research & Development (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Research & Development for 17 years, with the latest figure at $28.4 million in Q1 2026.
- Quarterly Research & Development fell 20.38% year-over-year to $28.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (down 92.0% YoY) and the FY2025 annual result came in at $14.4 million, down 80.65% from the prior year.
- Research & Development improved to $28.4 million in Q1 2026 per VNDA's latest filing, from -$65.9 million in the prior quarter.
- Over five years, Research & Development peaked at $35.7 million in Q1 2025 and troughed at -$65.9 million in Q4 2025.
- A 5-year average of $16.5 million and a median of $21.0 million in 2022 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 68.82% in 2025, down 431.98% in 2025.
- Over 5 years, Research & Development stood at $18.5 million in 2022, then jumped by 31.89% to $24.3 million in 2023, then retreated by 18.48% to $19.8 million in 2024, then sank by 431.98% to -$65.9 million in 2025, then soared by 143.17% to $28.4 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $28.4 million, -$65.9 million, and $22.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | 36.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.95 Mn |
| Mar 31, 2026 | 28.44 Mn |
| Dec 31, 2025 | -65.87 Mn |
| Sep 30, 2025 | 22.56 Mn |
| Jun 30, 2025 | 21.99 Mn |
| Mar 31, 2025 | 35.71 Mn |
| Dec 31, 2024 | 19.84 Mn |
| Sep 30, 2024 | 16.78 Mn |
| Jun 30, 2024 | 16.66 Mn |
| Mar 31, 2024 | 21.15 Mn |
| Dec 31, 2023 | 24.34 Mn |
| Sep 30, 2023 | 16.60 Mn |
| Jun 30, 2023 | 16.65 Mn |
| Mar 31, 2023 | 19.24 Mn |
| Dec 31, 2022 | 18.45 Mn |
| Sep 30, 2022 | 24.86 Mn |
| Jun 30, 2022 | 21.49 Mn |
| Mar 31, 2022 | 20.97 Mn |
| Dec 31, 2021 | 19.33 Mn |
| Sep 30, 2021 | 19.65 Mn |